Published on Web 05/17/2002
Total Synthesis of the Anticancer Natural Product OSW-1
Wensheng Yu and Zhendong Jin*
Contribution from the DiVision of Medicinal and Natural Products Chemistry,
College of Pharmacy, The UniVersity of Iowa, Iowa City, Iowa 52242
Received September 5, 2001
Abstract: The highly potent anticancer natural saponin OSW-1 has been successfully synthesized from
commercially available 5-androsten-3â-ol-17-one 79 in 10 operations with 28% overall yield. The key steps
in the total synthesis included a highly regio- and stereoselective selenium dioxide-mediated allylic oxidation
of 80 and a highly stereoselective 1,4-addition of R-alkoxy vinyl cuprates 68 to steroid 17(20)-en-16-one
12E to introduce the steroid side chain. This total synthesis demonstrated once again the versatile synthetic
applications of R-halo vinyl ether chemistry developed in our laboratories.
Introduction
OSW-1 (1), a highly potent anticancer natural product, and
its four natural analogues (2-5) have been isolated from the
bulbs of Ornithogalum saundersiae, a perennial grown in
southern Africa where it is cultivated as a cut flower and garden
plant.1 These natural products are members of the cholestane
glycosides. Their absolute structures have been determined by
extensive application of spectroscopic methods.1 The structural
novelty of compounds 1-5 is characterized by the attachment
of a disaccharide to the C-16 position of the steroid aglycone,
whereas compounds 4 and 5 have another glycosyl sugar
associated with the C-3 alcohol position of the steroid (Figure
1).
Compounds 1-5 exhibited extremely potent cytostatic activ-
ity against human promyelocytic leukemia HL-60 cells, showing
IC50 values ranging between 0.1 and 0.3 nM. The activity of
OSW-1 (1) in this assay is much more potent than that of
clinically used anticancer agents such as etoposide, adriamycin,
and methotrexate.2 OSW-1 (1), the main constituent of the bulbs,
exhibited exceptionally potent cytostatic activities against vari-
ous human malignant tumor cells.2 Its cytostatic activities are
from 10- to 100-fold more potent than some well-known
anticancer agents in clinical use, such as mitomycin C, adria-
mycin, cisplatin, camptothecin, and even taxol, but it has
significantly lower toxicity (IC50 1500 nM) to normal human
pulmonary cells.2 The surprising similarity of the cytotoxicity
profile of OSW-1 to that of cephalostatins,3 one of the most
active anticancer agents tested by NIH, with correlation coef-
ficient of 0.60-0.83, suggests they might have the same
Figure 1.
mechanism of action.4 It has been speculated by Fuchs that the
C22-oxonium ions might be the active intermediate for the
potent anticancer activity of OSW-1 (1) and cephalostatins.5
This suggests that OSW-1 (1) might represent a new class of
anticancer agents with a new mechanism of action. All of these
factors make OSW-1 (1) a very attractive synthetic target.4,6
As part of our program studying the chemistry and biology of
anticancer natural products, we recently initiated a project
directed toward the total synthesis of OSW-1 (1). We report
herein our full account of our studies toward the total synthesis
of this highly promising anticancer natural product.
Results and Discussion
Retrosynthetic Analysis. The C-20 carbon of OSW-1 has
the “normal” 20S configuration. Molecular mechanics calcula-
tions (MM2) have shown that compound 1 is about 3.1 kcal/
mol more stable than its 20R epimer 6, whereas 7 is about 2.4
kcal/mol more stable than 8 (Figure 2).7 Therefore, we thought
that it was not necessary to control the stereochemistry at C-20
during the synthesis and anticipated that compound 6 would
eventually epimerize to the thermodynamically more stable 1
at the end of the synthesis.
Figure 3 outlines our retrosynthetic analysis of OSW-1 (1).
Disconnection at the glycoside bond reveals the protected
* To whom correspondence should be addressed. E-mail:
(1) Kubo, S.; Mimaki, Y.; Terao M.; Sashida, Y.; Nikaido, T.; Ohmoto, T.
Phytochemitstry 1992, 31, 3969.
(2) Mimaki, Y.; Kuroda, M.; Kameyama, A.; Sashida, Y.; Hirano, T.; Oka,
K.; Maekawa, R.; Wada, T.; Sugita, K.; Beutler, J. A. Bioorg. Med. Chem.
Lett. 1997, 7, 633.
(3) (a) Pettit, G. R.; Inoue, M.; Kamano, Y.; Herald, D. L.; Arm, C.; Dufresne,
C.; Christie, N. D.; Schmidt, J. M.; Doubek, D. L.; Krupa, T. S. J. Am.
Chem. Soc. 1988, 110, 2006. (b) LaCour, T. G.; Guo, C.; Bhandaru, S.;
Boyd, M. R.; Fuchs, P. L. J. Am. Chem. Soc. 1998, 120, 692.
(4) Guo, C.; Fuchs, P. L. Tetrahedron Lett. 1998, 39, 1099.
(5) Guo, C.; LaCour, T. G.; Fuchs, P. L. Bioorg. Med. Chem. Lett. 1999, 9,
419.
(6) (a) Deng, S.; Yu, B.; Lou, Y.; Hui, Y. J. Org. Chem. 1999, 64, 202. (b)
Morzycki, J. W.; Gryszkiewicz, A.; Jastrzebska, I. Tetrahedron Lett. 2000,
41, 3751. (c) Yu, W.; Jin, Z. J. Am. Chem. Soc. 2001, 123, 3369.
(7) MM2 calculation was performed using CS Chem Ultra program on a
powerMac. The calculation results were consistent with experimental results,
see ref 10.
9
6576
J. AM. CHEM. SOC. 2002, 124, 6576-6583
10.1021/ja012119t CCC: $22.00 © 2002 American Chemical Society